Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease.
暂无分享,去创建一个
S. Reis | A. R. Neves | M. Pinheiro | J. Loureiro | M. Pereira | A. Granja | Ruben Pinheiro | Pinheiro R G R | Granja A | Loureiro J A | Pereira M C | Pinheiro M | Neves A R | Reis S
[1] M. J. Ramalho,et al. Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies , 2019, International journal of molecular sciences.
[2] G. Borge,et al. Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation. , 2018, Comprehensive reviews in food science and food safety.
[3] A. Neves,et al. Apo E-Functionalization of Solid Lipid Nanoparticles Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways. , 2017, Bioconjugate chemistry.
[4] Maria João Gomes,et al. Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier – from Targeting to Safe Administration , 2016, Journal of Neuroimmune Pharmacology.
[5] A. Neves,et al. Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer’s Disease , 2017, Molecules.
[6] A. Neves,et al. Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation , 2016, Drug design, development and therapy.
[7] R. Leblanc,et al. Crossing the blood-brain-barrier with transferrin conjugated carbon dots: A zebrafish model study. , 2016, Colloids and surfaces. B, Biointerfaces.
[8] Sourav Bhattacharjee,et al. DLS and zeta potential - What they are and what they are not? , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[9] Jing Liu,et al. Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol–dihydroartemisinin conjugate , 2016, Scientific Reports.
[10] L. Alpsoy,et al. Superparamagnetic iron oxide conjugated with folic acid and carboxylated quercetin for chemotherapy applications , 2016 .
[11] A. Neves,et al. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E , 2016, Journal of Nanobiotechnology.
[12] A. Neves,et al. Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects , 2016, Pharmaceutical Research.
[13] A. Neves,et al. Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E , 2015, Nanotechnology.
[14] M. Coelho,et al. Dual ligand immunoliposomes for drug delivery to the brain. , 2015, Colloids and surfaces. B, Biointerfaces.
[15] H. Valizadeh,et al. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. , 2015, Advanced pharmaceutical bulletin.
[16] M. Coelho,et al. Immunoliposomes doubly targeted to transferrin receptor and to α-synuclein , 2015, Future science OA.
[17] R. Bruno,et al. Endogenous and exogenous mediators of quercetin bioavailability. , 2015, The Journal of nutritional biochemistry.
[18] Mandy B. Esch,et al. TEER Measurement Techniques for In Vitro Barrier Model Systems , 2015, Journal of laboratory automation.
[19] Y. Kuo,et al. Neuroprotection against degeneration of sk-N-mc cells using neuron growth factor-encapsulated liposomes with surface cereport and transferrin. , 2014, Journal of pharmaceutical sciences.
[20] Y. Kuo,et al. Transferrin-grafted catanionic solid lipid nanoparticles for targeting delivery of saquinavir to the brain , 2014 .
[21] J. Loureiro,et al. Charged surfactants induce a non‐fibrillar aggregation pathway of amyloid‐beta peptide , 2013, Journal of peptide science : an official publication of the European Peptide Society.
[22] P. Couraud,et al. The hCMEC/D3 cell line as a model of the human blood brain barrier , 2013, Fluids and Barriers of the CNS.
[23] A. Neves,et al. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability , 2013, International journal of nanomedicine.
[24] Nicholas W. Smith,et al. Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. , 2012, ACS chemical neuroscience.
[25] S. Dall’Acqua,et al. The Photodegradation of Quercetin: Relation to Oxidation , 2012, Molecules.
[26] Sagar R. Mudshinge,et al. Nanoparticles: Emerging carriers for drug delivery. , 2011, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[27] Rishi Kapil,et al. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery , 2011, The Journal of pharmacy and pharmacology.
[28] Z. Zhang,et al. Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. , 2011, International journal of molecular medicine.
[29] Jintanaporn Wattanathorn,et al. Neuroprotective Effect of Quercetin Encapsulated Liposomes: A Novel Therapeutic Strategy against Alzheimer's Disease , 2010 .
[30] Wei Feng,et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. , 2009, International journal of pharmaceutics.
[31] R. Murthy,et al. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic®P85, an in vitro cell line and in vivo biodistribution studies on rat model , 2009, Journal of drug targeting.
[32] J. Davis,et al. Effects of the Dietary Flavonoid Quercetin Upon Performance and Health , 2009, Current sports medicine reports.
[33] D. Butterfield,et al. Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. , 2009, The Journal of nutritional biochemistry.
[34] M. Saraiva,et al. Design and biological activity of beta-sheet breaker peptide conjugates. , 2009, Biochemical and biophysical research communications.
[35] S. Krähenbühl,et al. The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies , 2008, Journal of neurochemistry.
[36] Robert Gurny,et al. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[37] Saengrawee Sutthiparinyanont,et al. Anxiety and cognitive effects of quercetin liposomes in rats. , 2008, Nanomedicine : nanotechnology, biology, and medicine.
[38] S. Litwin,et al. Quercetin reduces blood pressure in hypertensive subjects. , 2007, The Journal of nutrition.
[39] E. Park,et al. Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-κB and p38 MAPK in HMC-1 human mast cell line , 2007, Inflammation Research.
[40] V. Darley-Usmar,et al. Mechanism by which alcohol and wine polyphenols affect coronary heart disease risk. , 2007, Annals of epidemiology.
[41] Byeoung-Soo Park,et al. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. , 2005, Journal of agricultural and food chemistry.
[42] J. Greenwood,et al. Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[43] R. Sabaté,et al. Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis. , 2005, Langmuir : the ACS journal of surfaces and colloids.
[44] Chang Yong Lee,et al. Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration. , 2004, Journal of agricultural and food chemistry.
[45] M. R. Nilsson. Techniques to study amyloid fibril formation in vitro. , 2004, Methods.
[46] J. J. Balbach,et al. Site-Specific Identification of Non-β-Strand Conformations in Alzheimer's β-Amyloid Fibrils by Solid-State NMR , 2003 .
[47] Y. Song,et al. Neuroprotective effects of antioxidative flavonoids, quercetin, (+)-dihydroquercetin and quercetin 3-methyl ether, isolated from Opuntia ficus-indica var. saboten , 2003, Brain Research.
[48] R. Leapman,et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[49] Ralf Langen,et al. Structural and Dynamic Features of Alzheimer's Aβ Peptide in Amyloid Fibrils Studied by Site-directed Spin Labeling* , 2002, The Journal of Biological Chemistry.
[50] E. Rimm,et al. Flavonol and flavone intakes in US health professionals. , 2002, Journal of the American Dietetic Association.
[51] E. Morgan,et al. Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.
[52] A. Törrönen,et al. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. , 1999, Journal of agricultural and food chemistry.
[53] R. Müller,et al. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[54] A. Bast,et al. Influence of iron chelation on the antioxidant activity of flavonoids. , 1998, Biochemical pharmacology.
[55] R. Beavis,et al. Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure , 1995, Neuroscience Letters.
[56] C. Cotman,et al. Structure‐Activity Analyses of β‐Amyloid Peptides: Contributions of the β25–35 Region to Aggregation and Neurotoxicity , 1995 .
[57] H. Levine,et al. Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.
[58] A. I. Dorozhko,et al. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. , 1989, Biochemical pharmacology.
[59] A. Wach,et al. Quercetin content in some food and herbal samples , 2007 .